Kiromic BioPharma Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

false 0001792581 0001792581 2025-03-21 2025-03-21

 

 

 

 

Date of Report (Date of earliest event reported): March 21, 2025

 

(Exact name of registrant as specified in its charter)

 

 

(Address of principal executive offices) (Zip Code)

 

Registrant's telephone number, including area code (832) 968-4888

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

On March 21, 2025, Kiromic BioPharma, Inc. (the "Company") filed a voluntary petition for relief (the "Bankruptcy Filing") under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §101 et seq. (the "Bankruptcy Code"). The Bankruptcy Filing was filed in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court").

 

As a result of the Bankruptcy Filing, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will administer the Company's bankruptcy estate, including possibly liquidating the assets of the Company in accordance with the Bankruptcy Code. An initial hearing for creditors will be scheduled, and the Notice of Bankruptcy Case Filing will be sent to known creditors.

 

 

Pietro Bersani, Michael Nagel, Mike Catlin and Pamela Misajon tendered their resignations as members of the Company’s Board of Directors, which resignations were effective on March 21, 2025 as of immediately following the filing of the Bankruptcy Filing. The resignations of Pietro Bersani, Michael Nagel, Mike Catlin and Pamela Misajon are not the result of any disagreements with the Company regarding the Company’s operations, policies or practices. Each of the directors resigned due to the Company’s filing of the Bankruptcy Filing, which effectively eliminates the powers of the Company’s Board of Directors. Following the director resignations, the Company has no members serving on its Board of Directors.

 

The Company also terminated Brian Hungerford, the Company’s Chief Financial Officer, Leonardo Mirandola, the Company’s Chief Operating Officer and Scott Dahlbeck, the Company’s Chief of Staff, each effective March 21, 2025.

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

- 2 -